Which has higher earnings and valuation, LFMD or SERA?

LifeMD has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $193.33M 1.23 $14.35M $0.05 98.30 Sera Prognostics $80K 942.29 -$31.93M -$0.65 N/A

Is LFMD or SERA more profitable?

LifeMD has a net margin of 2.37% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Sera Prognostics -56,385.97% -41.02% -30.95%

Does the media refer more to LFMD or SERA?

In the previous week, Sera Prognostics had 4 more articles in the media than LifeMD. MarketBeat recorded 6 mentions for Sera Prognostics and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.39 beat Sera Prognostics' score of -0.02 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SERA or BDSX more profitable?

Biodesix has a net margin of -33.26% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -56,385.97% -41.02% -30.95% Biodesix -33.26% -2,101.40% -35.65%

Does the media prefer SERA or BDSX?

In the previous week, Sera Prognostics had 4 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for Sera Prognostics and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.36 beat Sera Prognostics' score of -0.02 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SERA or XGN?

Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sera Prognostics $80K 942.29 -$31.93M -$0.65 N/A Exagen $66.57M 1.59 -$19.95M -$0.89 N/A

Is SERA or XGN more profitable?

Exagen has a net margin of -29.49% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -56,385.97% -41.02% -30.95% Exagen -29.49% -94.37% -28.96%

Does the media prefer SERA or XGN?

In the previous week, Sera Prognostics had 4 more articles in the media than Exagen. MarketBeat recorded 6 mentions for Sera Prognostics and 2 mentions for Exagen. Exagen's average media sentiment score of 1.23 beat Sera Prognostics' score of -0.02 indicating that Exagen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Exagen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BNR or SERA?

Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 185.71%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Burning Rock Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Burning Rock Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sera Prognostics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media refer more to BNR or SERA?

In the previous week, Sera Prognostics had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 6 mentions for Sera Prognostics and 3 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.63 beat Sera Prognostics' score of -0.02 indicating that Burning Rock Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Burning Rock Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Sera Prognostics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sera Prognostics (SERA) Competitors

$1.92 -0.08 (-3.75%)

As of 02:47 PM Eastern

Compare

SERA vs. SBC, LFMD, BDSX, XGN, and BNR

Should you buy Sera Prognostics stock or one of its competitors? MarketBeat compares Sera Prognostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sera Prognostics include SBC Medical Group (SBC), LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), and Burning Rock Biotech (BNR). These companies are all part of the "healthcare" industry.

How does Sera Prognostics compare to SBC Medical Group?

Sera Prognostics (NASDAQ:SERA) and SBC Medical Group (NASDAQ:SBC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

SBC Medical Group has a net margin of 24.09% compared to Sera Prognostics' net margin of -56,385.97%. SBC Medical Group's return on equity of 15.90% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
SBC Medical Group	24.09%	15.90%	11.61%

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 60.8% of SBC Medical Group shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by insiders. Comparatively, 81.7% of SBC Medical Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

SBC Medical Group has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than SBC Medical Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	942.29	-$31.93M	-$0.65	N/A
SBC Medical Group	$169.34M	1.81	$50.99M	$0.39	7.65

In the previous week, Sera Prognostics had 5 more articles in the media than SBC Medical Group. MarketBeat recorded 6 mentions for Sera Prognostics and 1 mentions for SBC Medical Group. SBC Medical Group's average media sentiment score of 1.89 beat Sera Prognostics' score of -0.02 indicating that SBC Medical Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Neutral
SBC Medical Group	Very Positive

Sera Prognostics currently has a consensus target price of $5.50, suggesting a potential upside of 185.71%. SBC Medical Group has a consensus target price of $8.50, suggesting a potential upside of 184.76%. Given Sera Prognostics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Sera Prognostics is more favorable than SBC Medical Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
SBC Medical Group	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Sera Prognostics has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, SBC Medical Group has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

Summary

SBC Medical Group beats Sera Prognostics on 11 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

LifeMD has a net margin of 2.37% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

LifeMD presently has a consensus target price of $9.14, indicating a potential upside of 86.02%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 185.71%. Given Sera Prognostics' higher probable upside, analysts clearly believe Sera Prognostics is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

LifeMD has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$193.33M	1.23	$14.35M	$0.05	98.30
Sera Prognostics	$80K	942.29	-$31.93M	-$0.65	N/A

In the previous week, Sera Prognostics had 4 more articles in the media than LifeMD. MarketBeat recorded 6 mentions for Sera Prognostics and 2 mentions for LifeMD. LifeMD's average media sentiment score of 0.39 beat Sera Prognostics' score of -0.02 indicating that LifeMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

LifeMD has a beta of 1.98, indicating that its share price is 98% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

35.5% of LifeMD shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 18.4% of LifeMD shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

LifeMD beats Sera Prognostics on 11 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Biodesix?

Sera Prognostics (NASDAQ:SERA) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Sera Prognostics currently has a consensus price target of $5.50, suggesting a potential upside of 185.71%. Biodesix has a consensus price target of $22.00, suggesting a potential upside of 41.91%. Given Sera Prognostics' stronger consensus rating and higher possible upside, research analysts plainly believe Sera Prognostics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Biodesix	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Sera Prognostics had 4 more articles in the media than Biodesix. MarketBeat recorded 6 mentions for Sera Prognostics and 2 mentions for Biodesix. Biodesix's average media sentiment score of 1.36 beat Sera Prognostics' score of -0.02 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sera Prognostics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Sera Prognostics has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	942.29	-$31.93M	-$0.65	N/A
Biodesix	$96.10M	1.67	-$35.26M	-$4.06	N/A

Biodesix has a net margin of -33.26% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Biodesix	-33.26%	-2,101.40%	-35.65%

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 23.2% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sera Prognostics beats Biodesix on 12 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Exagen?

Sera Prognostics (NASDAQ:SERA) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Sera Prognostics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Exagen has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Sera Prognostics presently has a consensus target price of $5.50, indicating a potential upside of 185.71%. Exagen has a consensus target price of $9.25, indicating a potential upside of 111.19%. Given Sera Prognostics' higher possible upside, research analysts plainly believe Sera Prognostics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Exagen has a net margin of -29.49% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Exagen	-29.49%	-94.37%	-28.96%

Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	942.29	-$31.93M	-$0.65	N/A
Exagen	$66.57M	1.59	-$19.95M	-$0.89	N/A

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by company insiders. Comparatively, 10.4% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Sera Prognostics had 4 more articles in the media than Exagen. MarketBeat recorded 6 mentions for Sera Prognostics and 2 mentions for Exagen. Exagen's average media sentiment score of 1.23 beat Sera Prognostics' score of -0.02 indicating that Exagen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Exagen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Exagen beats Sera Prognostics on 9 of the 17 factors compared between the two stocks.

How does Sera Prognostics compare to Burning Rock Biotech?

Burning Rock Biotech (NASDAQ:BNR) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Sera Prognostics had 3 more articles in the media than Burning Rock Biotech. MarketBeat recorded 6 mentions for Sera Prognostics and 3 mentions for Burning Rock Biotech. Burning Rock Biotech's average media sentiment score of 1.63 beat Sera Prognostics' score of -0.02 indicating that Burning Rock Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Burning Rock Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Sera Prognostics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 185.71%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Burning Rock Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Burning Rock Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Burning Rock Biotech has higher revenue and earnings than Sera Prognostics. Burning Rock Biotech is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Burning Rock Biotech	$514.43M	0.18	-$7.92M	-$0.82	N/A
Sera Prognostics	$80K	942.29	-$31.93M	-$0.65	N/A

Burning Rock Biotech has a net margin of -11.57% compared to Sera Prognostics' net margin of -56,385.97%. Burning Rock Biotech's return on equity of -10.89% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Burning Rock Biotech	-11.57%	-10.89%	-7.31%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

Burning Rock Biotech has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

30.0% of Burning Rock Biotech shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 30.3% of Burning Rock Biotech shares are owned by insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Sera Prognostics beats Burning Rock Biotech on 9 of the 17 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$75.38M	$8.90B	$6.53B	$11.87B
Dividend Yield	N/A	1.76%	2.67%	5.62%
P/E Ratio	-2.96	25.34	24.80	24.00
Price / Sales	942.29	17.92	473.79	86.25
Price / Cash	N/A	90.88	43.05	54.72
Price / Book	0.99	5.60	10.50	6.79
Net Income	-$31.93M	$179.69M	$3.56B	$337.41M
7 Day Performance	-14.06%	-0.07%	-2.12%	-1.35%
1 Month Performance	11.27%	8.76%	0.56%	1.44%
1 Year Performance	28.33%	2.24%	21.93%	25.96%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	3.3667 of 5 stars	$1.93 -3.8%	$5.50 +185.7%	+34.2%	$75.38M	$80K	N/A	120	News Coverage
SBC SBC Medical Group	3.9819 of 5 stars	$2.99 +1.0%	$8.50 +184.3%	-36.8%	$303.63M	$173.61M	7.67	N/A
LFMD LifeMD	3.1073 of 5 stars	$4.82 -4.0%	$9.14 +89.7%	-59.1%	$242.78M	$194.05M	96.42	230
BDSX Biodesix	3.8057 of 5 stars	$15.36 +2.7%	$22.00 +43.2%	+127.4%	$154.82M	$88.50M	N/A	220	Positive News
XGN Exagen	3.4302 of 5 stars	$4.31 +2.6%	$9.25 +114.6%	-43.1%	$101.47M	$66.57M	N/A	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. SBC, LFMD, BDSX, XGN, and BNR

How does Sera Prognostics compare to SBC Medical Group?

Summary

How does Sera Prognostics compare to LifeMD?

Summary

How does Sera Prognostics compare to Biodesix?

Summary

How does Sera Prognostics compare to Exagen?

Summary

How does Sera Prognostics compare to Burning Rock Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. SBC, LFMD, BDSX, XGN, and BNR

How does Sera Prognostics compare to SBC Medical Group?

Is SERA or SBC more profitable?

Do institutionals and insiders hold more shares of SERA or SBC?

Which has preferable valuation and earnings, SERA or SBC?

Does the media refer more to SERA or SBC?

Do analysts recommend SERA or SBC?

Which has more volatility & risk, SERA or SBC?

Summary

How does Sera Prognostics compare to LifeMD?

Is LFMD or SERA more profitable?

Do analysts prefer LFMD or SERA?

Which has higher earnings and valuation, LFMD or SERA?

Does the media refer more to LFMD or SERA?

Which has more volatility & risk, LFMD or SERA?

Do insiders and institutionals hold more shares of LFMD or SERA?

Summary

How does Sera Prognostics compare to Biodesix?

Do analysts prefer SERA or BDSX?

Does the media prefer SERA or BDSX?

Which has more risk & volatility, SERA or BDSX?

Which has better valuation & earnings, SERA or BDSX?

Is SERA or BDSX more profitable?

Do institutionals and insiders hold more shares of SERA or BDSX?

Summary

How does Sera Prognostics compare to Exagen?

Which has more volatility & risk, SERA or XGN?

Do analysts rate SERA or XGN?

Is SERA or XGN more profitable?

Which has stronger earnings and valuation, SERA or XGN?

Do institutionals & insiders believe in SERA or XGN?

Does the media prefer SERA or XGN?

Summary

How does Sera Prognostics compare to Burning Rock Biotech?

Does the media refer more to BNR or SERA?

Do analysts prefer BNR or SERA?

Which has stronger valuation & earnings, BNR or SERA?

Is BNR or SERA more profitable?

Which has more risk & volatility, BNR or SERA?

Do insiders & institutionals believe in BNR or SERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools